Dicerna Pharmaceuticals
Mar 6, 2014

Dicerna to Present at Two Upcoming Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced that members of the management team will present at two upcoming conferences:

About Dicerna Pharmaceuticals, Inc.

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas and intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.

Company:
Dicerna Pharmaceuticals, Inc.
James B. Weissman, 617-621-8097
Chief Business Officer
or
Media:
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
Senior Vice President
chris@macbiocom.com

Source: Dicerna Pharmaceuticals, Inc.

News Provided by Acquire Media